PAX5 encodes a master regulator of B-cell development. It fuses to other genes associated with acute lymphoblastoid leukemia (ALL). These fusion products are potent dominant-negative (DN) inhibitors of wild-type PAX5, resulting in a blockade of B-cell differentiation. Here, we show that multimerization of PAX5 DNA-binding domain (DBD) is necessary and sufficient to cause extremely stable chromatin binding and DN activity. ALL-associated PAX5-C20S results from fusion of the N-terminal region of PAX5, including its paired DBD, to the C-terminus of C20orf112, a protein of unknown function. We report that PAX5-C20S is a tetramer, which interacts extraordinarily stably with chromatin as determined by Fluorescence Recovery After Photobleaching in living cells. Tetramerization, stable chromatin binding and DN activity all require a putative five-turn amphipathic a-helix at the C-terminus of C20orf112, and does not require potential corepressor binding peptides elsewhere in the sequence. In vitro, the monomeric PAX5 DBD and PAX5-C20S binds a PAX5-binding site with equal affinity when it is at the center of an oligonucleotide too short to bind to more than one PAX5 DBD. But, PAX5-C20S binds the same sequence with 10-fold higher affinity than the monomeric PAX5 DBD when it is in a long DNA molecule. We suggest that the increased affinity results from interactions of one or more of the additional DBDs with neighboring non-specific sites in a long DNA molecule, and that this can account for the increased stability of PAX5-C20S chromatin binding compared with wild-type PAX5, resulting in DN activity by competition for binding to PAX5-target sites. Consistent with this model, the ALL-associated PAX5 fused to ETV6 or the multimerization domain of ETV6 SAM results in stable chromatin binding and DN activity. In addition, PAX5 DBD fused to artificial dimerization, trimerization and tetramerization domains results in parallel increases in the stability of chromatin binding and DN activity. Our studies suggest that oncogenic fusion proteins that retain the DBD of the transcription factor (TF) and the multimerization sequence of the partner protein can act in a DN manner by multimerizing and binding avidly to gene targets, preventing the normal TF from binding and inducing expression of its target genes. Inhibition of this multimeriztion may provide a novel therapeutic approach for cancers with this or similar fusion proteins.
Introduction
Gene fusions caused by chromosomal translocations contribute to the pathogenesis of many human neoplasms (Edwards, 2010) . Most rearrangements are one of the two types: (1) 'promoter swapping,' which juxtaposes proto-oncogenes to abnormal transcriptional regulatory elements, leading to aberrant timing and/or expression level of a normal protein or (2) fusions of two genes leading to expression of a chimeric fusion protein with abnormal function (Gasparini et al., 2007) . Most oncogenic chimeric genes in the second class involve tyrosine kinases or transcription factors (TF) (Mitelman et al., 2007) . For oncogenic TF fusions, the resulting chimeric protein usually retains the TF DNA-binding domain (DBD) and results in either enhanced or reduced expression of target genes of the wild-type (wt) TF, promoting proliferation or blocking differentiation (O'Neil and Look, 2007) . In many cases, oncogenic TF fusions exert dominant-negative (DN) activity over the wt TF expressed at a similar level from an unrearranged allele in the same cell (Pabst and Mueller, 2007) . In many of these examples, oncogenic TF fusions may act as DNs because the fusion proteins contain repression domains that recruit corepressors to target genes, inhibiting their expression despite co-binding of the wt protein to repeated binding sites in the same control regions (Grignani et al., 1998; Lin et al., 1998) . However, in some cases, oncogenic DN-TFs are generated from fusions of DBDs to structural proteins (for example, elastin, Bousquet et al., 2007;  or a myosin, Liu et al., 1993) that have oligomerization domains, but no known repression domains. How oligomerization contributes to aberrant transcriptional activity is incompletely understood (So and Cleary, 2004) .
PAX5 encodes a TF essential for B-cell differentiation that activates a number of B cell-specific genes and represses several genes specific for other hematopoietic lineages (Cobaleda et al., 2007) . We and others have cloned a number of PAX5 fusion genes from acute lymphoblastic leukemia (ALL) cells ( Supplementary  Table S1 ), including the two most commonly studied here, PAX5-C20orf112 Kawamata et al., 2008) and PAX5-ETV6 (Cazzaniga et al., 2001) . In each case, the generated fusion proteins retain the N-terminal PAX5 DBD which is a paired domain that binds DNA as a monomer (Xu et al., 1995) , and lack the C-terminal PAX5 activation domain (Dorfler and Busslinger, 1996) . These fusion products are able to block the expression of PAX5-target genes and are associated with a block in B-cell differentiation (Bousquet et al., 2007; Cobaleda et al., 2007; Fazio et al, 2008; Kawamata et al, 2008) . Here, we show that multimerization of the PAX5 DBD by the fusion partner is necessary and sufficient for DN activity. Multimerization greatly increases the stability of the proteinchromatin interaction in living cells, probably through cooperative binding of the multimerized DBD to neighboring, non-specific low-affinity DNA sites. The resulting high-affinity binding of the fusion protein competes with wt PAX5 binding to target genes.
Inhibiting multimerization of the DBD interferes with stable chromatin binding and the resulting DN activity. Consequently, this would likely be a useful therapeutic strategy for either ALL with PAX5 fusions or other cancers with similar fusion proteins.
Results
Structural determinants of DN activity Two types of fusion genes associated with ALL involve PAX5 and C20orf112, PAX5-C20S resulting in an in-frame fusion of PAX5 exon 5 to C20orf112 exon 8 ( Figure 1a ), and PAX5-C20L generating an in-frame fusion of PAX5 exon 8 to C20orf112 exon 3 Kawamata et al., 2008) . We choose to focus on PAX5-C20S because it represents the smallest region of C20 still associated with the development of ALL. Analysis of the C20orf112 sequence in PAX5-C20S ( Figure 1b ) revealed three regions that may contribute to DN activity: a putative binding motif for the CtBP corepressor (Chinnadurai, 2002) , a Ser-Thr-Pro rich region and the last 35 amino acids (aa) predicted to adopt an a-helical secondary structure (http://bioinf. cs.ucl.ac.uk/psipred/). The CtBP motif and the putative a-helical domain are highly conserved in C20orf112 orthologs from insects to humans (Supplementary Figure S1 ). To determine which regions of C20S are responsible for PAX5-C20S DN activity over wt PAX5, we performed transient transfection assays with a luciferase reporter with three PAX5-binding sites (Cobaleda et al., 2007) , C20orf112, PAX5-C20S, PAX5DDBD-C20S with the paired DBD deleted and PAX5-Exon5 (encoded by PAX5 exons 1-5, the portion of PAX5 in PAX5-C20S). The PAX5 DBD (PD (DBD)), an octapeptide motif bound by Groucho-family corepressors (O), and a nuclear localization sequence (N) are included in PAX5-C20S while its partial homeodomain (HD), activation domain (TAD) and inhibitory domain (ID) are not. Black arrows indicate points of fusion. (b) Analysis of C20orf112 sequence in PAX5-C20S reveals three regions that may contribute to DN activity: a CtBP binding motif (PxDLSxK), a serine-threonine-proline (Ser-Thr-Pro)-rich region and a putative a-helical region. Constructs that contain bracketed parts of C20S are YFP-PAX5-C20-MD that fuses only the a-helical region, and YFP-PAX5-C20DMD that fuses only the PxDLSxK motif and the Ser-Thr-Pro rich region.
Dominant-negative mechanism of PAX5 fusions N Kawamata et al derived from the murine CD19 promoter (Dorfler and Busslinger, 1996) . Experiments were performed with expression vectors for wt PAX5, PAX5-C20S and derivatives of PAX5-C20S with yellow fluorescent protein (YFP) fused to their N-termini ( Figure 2a ) in preparation for in vivo fluorescence studies described below. The YFP-N-terminal fusion had little effect either on activation by PAX5-wt or on the DN activity of PAX5-C20S (compare Figure 2a and Supplementary Figure S2 ). DN activity was observed even though YFP-PAX5-C20S was expressed at lower levels than YFP-PAX5-wt (Supplementary Figure S3 ). Deletion of the CtBP binding motif and the Ser-Thr-Pro rich regions of YFP-PAX5-C20S, but retention of the putative a-helical region (YFP-PAX5-C20-MD; Figure 1b ), did not diminish DN activity (Figure 2a ). In contrast, deletion of the putative a-helical region, but retention of the CtBP binding motif and the Ser-Thr-Pro region (YFP-PAX5-C20DMD; Figure 1b ) nearly eliminated DN activity (Figure 2a ), indicating that the proposed ahelical region of C20S is required for suppression of wt PAX5 activity. The slight reduction in luciferase observed with YFP-PAX5-C20DMD was likely due to competition for binding to the reporter by the deleted protein that lacks an activation domain.
Results from chromatin immunoprecipitation assays using antibody specific for the C-terminus of wt PAX5 indicated that PAX5-C20S expression significantly reduced binding of wt PAX5 to the BLK PAX5-target gene in Nalm6 B-cell leukemia cells, even though the two proteins were expressed at similar levels (Kawamata et al., 2008) . We speculated that the C20orf112 C-terminal region might induce oligomerization or multimerization of the PAX5 DBD, increasing PAX5-C20S DNAbinding affinity by cooperative binding by two or more DBDs in the multimer to neighboring sites in chromosomal DNA. High-affinity binding by the fusion might then compete for binding by wt PAX5 at equal concentrations. To test this hypothesis, we performed Fluorescence Recovery After Photobleaching (FRAP) experiments in living cells to measure the stability of chromatin binding by wt PAX5 and PAX5-C20S in vivo. Fluorescence signals from most TF-fluorescent protein fusions recover quickly after photobleaching a region of the nucleus (t 1/2 o10 s) (Phair et al., 2004) . However, wt PAX5 displayed unusually stable binding with a t 1/2 B24 s (Figures 2b and c) , consistent with a recent report that several members of the PAX family TFs in general exhibit slow recovery times (Elvenes et al., 2010) . Remarkably, the leukemogenic PAX5-C20S fusion To examine which regions of the fusion protein are responsible for its unusually slow nuclear mobility, we performed FRAP assays with several deletions of PAX5-C20S fused to YFP. Deletion of the PAX5 DBD ( Figure 1a ) showed that it is required for stable binding (Figure 2d ), suggesting that low PAX5-C20S nuclear mobility requires binding to DNA in chromatin. The DBD was also required for DN activity in the reporter assay (Supplementary Figure S4A ). All of these YFP-labeled constructs localized to the nucleus (Supplementary Figure S4B ). FRAP assays with YFP-PAX5-C20DMD and YFP-PAX5-C20MD (Figure 2e ) showed that the putative a-helical region at the C-terminus is required and sufficient for the decreased mobility of PAX5-C20S; decreased mobility does not require either the CtBP binding motif or the Ser-Thr-Pro rich region. FRAP was also performed with YFP fused to the region of PAX5 in PAX5-C20S encoded by exons 1-5 'PAX5-Exon 5' (Figure 1a ) which gave a t 1/2 E4 s ( Figure 2d ). Consequently, the region of PAX5 C-terminal to the portion in PAX5-C20S is required for the slow nuclear mobility of wt PAX5. However, this cannot contribute to the stability of PAX5-C20S chromatin binding as it is absent from the fusion protein. Also, a potential octapeptide Groucho repression motif in exon 5 of PAX5 ('O' in Figure 1a ) does not contribute significantly to the DN activity of PAX5-C20S, as mutation Y179E in PAX5 disrupts interactions with the Groucho proteins (Eberhard et al., 2000) and had no effect on the stable chromatin binding of PAX5-C20S and only a minor effect on the DN activity of either PAX5-C20S or the PAX5-p53tetra fusion ( Supplementary Figures S5A and B) . Thus, the putative C-terminal a-helical region of PAX5-C20S greatly increases the stability of chromatin binding and is required for DN activity.
We also examined the product of the PAX5-ETV6 fusion gene, the most frequently reported PAX5 fusion in ALL ( Supplementary Table S1 ). The portion of ETV6 fused to the N-terminus of PAX5 contains an SAM domain whose crystal structure reveals a head-to-tail polymer (Kim et al., 2001 ) that we speculated might result in stable chromatin binding as we observed for PAX5-C20S. Indeed, both YFP fused to PAX5-ETV6 and to the N-terminal region of PAX5 fused to the SAM domain alone (YFP-PAX5-SAM) exhibited stable chromatin binding comparable to that of YFP-PAX5-C20S (estimated t 1/2 E200 s) (Supplementary Figure S5C ). Reporter gene assays showed that the SAM domain alone was sufficient to generate a potent DN activity equivalent to that of PAX5-ETV6 (Supplementary Figure S5D ).
PAX5-C20S has a C-terminal homo-multimerization domain
A helical-wheel projection (Figure 3a) of the C20S C-terminal sequence revealed 4-3 hydrophobic heptad repeats, consistent with an amphipathic helix. To determine if the predicted amphipathic a-helix is involved in PAX5-C20S oligomerization, we expressed separate fusions of YFP and cyan fluorescent protein (CFP) to C20orf112 residues 391-436 ('C20HL') in transfected 293T cells and performed fluorescence resonance energy transfer (FRET) assays by flow cytometry, a sensitive method for detecting the interaction of two proteins in vivo in thousands of individual cells (Siegel et al., 2000) . YFP-C20HL and CFP-C20HL showed strong FRET signals, similar to the positive control of a CFP-YFP tandem fusion ( Figure 3b ). FRET was also observed using YFP-PAX5-C20S and CFP-PAX5-C20S (Figure 3b ), suggesting that PAX5-C20S fusion proteins associate through an a-helical region at their C-termini.
To confirm oligomerization of PAX5-C20S, YFP fusion proteins in nuclear extract (Wang et al., 2001) from the same cells used for the FRAP studies were subjected to gel filtration chromatography (Figure 3c ). YFP and YFP-PAX5-wt eluted as predicted for monomeric proteins. However, YFP-PAX5-C20S eluted much earlier than YFP-PAX5-wt, consistent with formation of a multimer. Purified PAX5-C20S-His 6 (31.2 kDa) expressed in Escherichia coli eluted just after the peak of Aldolase (158 kDa), consistent with a tetramer (Figure 3d ). In contrast, when PAX5-Exon5-His 6 , containing only the portion of PAX5 included in PAX5-C20S (25.4 kDa), was similarly expressed in and purified from E. coli, it eluted as expected for a monomer (Figure 3d ). Interestingly, in gel filtration the YFP-PAX5-SAM fusion eluted in multiple fractions including the void volume (42 MDa), indicating that it can form polymeric species from dimer to high-order polymers (data not shown), consistent with the crystal structure of the SAM domain.
We also co-expressed PAX5-C20S with either YFP-PAX5-C20S or YFP-PAX5-wt in 293T cells and performed co-immunoprecipitation assays with anti-YFP antibody. As expected from the results indicating that PAX5-C20S forms a tetramer, PAX5-C20S coimmunoprecipitated with YFP-PAX5-C20S. However, importantly, PAX5-C20S failed to co-immunoprecipitate with YFP-PAX5-wt (Figure 3e ), indicating that while PAX5-C20S forms homo-multimers, it does not interact with monomeric wt PAX5 expressed in the same cell. Thus, the DN activity of PAX5-C20S does not result from the formation of mixed multimers between wt PAX5 and the oncogenic, multimeric fusion protein.
Multimerization of PAX5 and DN activity
Mutation of leucine 421 ( Figure 3a) to proline near the middle of the proposed C-terminal amphipathic helix of C20orf112 is predicted to greatly reduce the propensity of this sequence to form interacting a-helices (using Marcoil, Delorenzi and Speed, 2002; Paircoil2, McDonnell et al., 2006; and COILS/PCOILS Gruber et al., 2005 programs) . Gel filtration showed that this mutation converts YFP-PAX5-C20S to a monomer (Figure 3c) . Consistent with the model that stable chromatin binding and DN activity of PAX5-C20S results from multivalent Dominant-negative mechanism of PAX5 fusions N Kawamata et al interactions between several DBDs in a PAX5-C20S multimer and several sites in DNA, the L421P mutation caused both a substantial decrease in FRAP t 1/2 ( Figure 4a ) and a prominent loss of DN activity (Figure 4b) .
To test the hypothesis further, we fused the Nterminal region of PAX5 to previously characterized protein oligomerization domains known to form a dimer, a trimer or a tetramer (Figure 5a ). The p53 tetramerization domain (p53tetra, aa 305-360) has been studied extensively and shown to behave as either a monomer or a dimer with single point mutants L344P and L344R, respectively (Davison et al., 2001) . In the exhaustively studied p53 protein, the tetramerization domain is not known to function directly in transcriptional repression by interacting with corepressors. The foldon domain is a trimerization module from the Cterminal 27 aa of phage T4 fibritin (Letarov et al., 1999) . The fusion proteins expressed in p53-minus H1299 cells eluted from a gel filtration column according to their predicted oligomeric states (Figure 5b ). The peaks of YFP-PAX5-C20S and YFP-PAX5-p53tetra eluted in the same fractions (Figures 3c and 5b) , consistent with the conclusion that the C20orf112 C-terminal region is a tetramerization domain based on gel filtration of PAX5-C20S-His 6 expressed in E. coli (Figure 3d ). Importantly, FRAP assays of these artificial multimers showed increasing stability of protein-chromatin interactions in vivo in parallel with the increasing number of PAX5 DBDs in the multimer (Figure 5c ). The t 1/2 increased by B2to 3-fold as the oligomeric state of the fusion increased successively from monomer to dimer and so on. Significantly, luciferase reporter assays showed that DN activity increased in parallel with the number of monomers in the multimer and the resulting increase in stability of chromatin binding (Figure 5d ). Fusion of the p53 tetramerization domain generated DN activity comparable to that of PAX5-C20S. Further, to confirm if this artificial fusion PAX5 which tetramerizes via the p53 tetramerization domain suppressed PAX5 downstream target genes, we transfected YFP-PAX5-p53tetra, YFP-PAX5-C20S or YFP constructs into Daudi cells (Burkitt B-cell lymphoma cell line). YFP-positive cells were sorted and expression levels of PAX5 downstream target genes were examined by semi-quantitative RT-PCR. Expression levels of two major PAX5 downstream target genes (BLK and BCAR3) were suppressed by YFP-PAX5-p53tetra as strongly as by YFP-PAX5-C20S (Figure 5e ).
PAX5-C20S binds DNA in vitro with 10-fold higher affinity than a monomeric PAX5 DBD The unusual stability of chromatin binding by PAX5-C20S and PAX5-ETV6 might be accounted for by multivalency, that is, the binding of multiple DBDs in the same stable multimer to nearby specific and nonspecific sites in chromosomal DNA. Since K D s of TF DBDs for non-specific sites are often in the 10 À4 to 10 À6 M range, the affinity of such a multimer would increase as the number of DBDs in the multimer increases. Such an effect would be missed in the earlier reported in vitro assays of DNA binding that did not show a difference in affinity between wt PAX5 and PAX5-C20S (Kawamata et al., 2008) because the short oligonucleotide probe used could be bound by only a single DBD. To test this possibility, we performed in vitro DNA-binding assays (electrophoretic mobility shift assays) using recombinant PAX5 proteins purified from E. coli and long unlabeled DNA molecules in competition experiments with a short 32 P-labeled oligonucleotide probe containing a single PAX5-binding site. We were not able to express full-length wt PAX5 at a high level in E. coli, and consequently compared PAX5-C20S with the portion of PAX5 that is fused to C20orf112 in PAX5-C20S (Figure 1a , PAX5-Exon5). As expected for a tetramer, PAX5-C20S generated a slower mobility electrophoretic mobility shift assay band than the monomeric PAX5 paired DBD in PAX5-Exon5 Dominant-negative mechanism of PAX5 fusions N Kawamata et al ( Figure 6 ). The PAX5-C20S DNA-protein complexes resolved into two bands, probably due to binding of one or two oligonucleotide probes to separate DBDs in the tetramer. Failure to observe three or four bands may indicate that steric restraints restrict binding to more than two oligonucleotide probes. To assay differences in binding affinity to short and long DNA molecules, we added increasing amounts of cold competitor DNAs to a labeled 46 bp probe before the addition of protein. The 46-bp labeled probe is bound by a single PAX5 paired DBD that protects 28 bp at the center of the probe from DNase I digestion (Czerny et al., 1993; Xu et al., 1995) . When the unlabeled probe was added as competitor, it competed equally the binding of the labeled Figure 6 PAX5-C20S tetramer has greater affinity in vitro for a PAX5 site in a long DNA molecule than monomeric PAX5-Exon5. (a) Electrophoretic mobility shift assay using a 46-bp 32 P-labeled high-affinity PAX5-binding site (PAX5BS) derived from the CD19 promoter (Czerny et al., 1993) . Increasing amounts of unlabeled 46 bp PAX5BS (0.1, 0.4, 1.6, 6.4, 26, 100 and 400 nM) were added before addition of protein to the binding reaction. The fraction of labeled 46 bp PAX5BS probe bound by protein (PAX5-Exon5 or PAX5-C20S) was calculated and plotted to the right relative to the amount bound without competitor. Results from two independent assays are indicated by the green squares and blue diamond symbols for PAX5-Exon5 and the red triangles and black circles for PAX5-C20. (b, c) Performed as in (a) except the unlabeled competitor DNA (0.1, 0.3, 1.0, 3, 10, 30 and 100 nM) was a 5.15-kb plasmid with one or two copies (separated by 2 kb) of the 46-bp PAX5BS cloned into it. The data were fit by the variable slope sigmoid equation (see Materials and methods and Supplementary Materials). Dominant-negative mechanism of PAX5 fusions N Kawamata et al probe to the PAX5-Exon 5 monomer and the PAX5-C20S tetramer (Figure 6a ). However, significantly, when a 5.15-kb plasmid with a single PAX5-binding site was used as competitor, competition to 50% probe binding was observed at one tenth the competitor concentration for PAX5-C20S compared with PAX5-Exon5 (Figure 6b) , indicating that PAX5-C20S has 10-fold higher affinity for a PAX5 site in a long DNA molecule, like cellular DNA, than a monomeric PAX5 DBD. As the plasmid contains a single specific PAX5-binding site, the increased affinity probably results from interactions of one or more of the additional DBDs in the tetramer with non-specific sites in the long DNA. The plasmid competed probe binding to the monomeric PAX5-Exon5 at a lower concentration than the cold 46 bp probe (50% probe binding at 1 versus 9 nM), because in the binding reactions with the plasmid competition also occurs from the high number of lowaffinity non-specific sites in the plasmid-every basepair of the 5.15-kb plasmid constitutes the first basepair of another non-specific site.
YFP-PAX5p53tetra-L344P
A plasmid with two PAX5-binding sites separated by 2 kb competed for binding to the monomeric PAX5-Exon5 at about one-half the concentration of the plasmid with a single PAX5-binding site (Figure 6c ) as expected, since the concentration of specific sites is two times higher for the same concentration of plasmid. The increased affinity of PAX5-C20S for the plasmid with two PAX5 sites remained 10-fold higher than for monomeric PAX5-Exon5. Similar results were observed for the luciferase reporter plasmid with three high-affinity PAX5-binding sites separated by 49 bp between the centers of the sites (data not shown). These results support the conclusion that the increased affinity of PAX5-C20S results from interactions of one or more of the three extra DBDs in the PAX5-C20S tetramer with a neighboring non-specific site or sites. Otherwise, one would have expected a much greater increase in affinity for plasmids with two and three specific sites compared with the plasmid with a single specific site.
Inhibition of PAX5-C20S DN activity by expression of the C20S tetramerization domain
Our data support the model that tetramerization of the PAX5 DBD via the C-terminal region of C20S causes high-affinity binding of the oncogenic TF fusion to its cognate DNA binding sites, competing for binding by wt PAX5. This model suggests that co-expression of the C20orf112 tetramerization domain not fused to a PAX5 DBD would disrupt tetramerization of the DBD via hetero-oligomerization, and consequently interfere with PAX5-C20S DN activity. To test this, we co-expressed PAX5-DDBD-C20S with PAX5-C20S, using a fourfold excess of the PAX5-DDBD-C20S vector. DN activity was nearly eliminated as measured by reporter assay (Figure 7a) . A similar result has been reported for disruption of both the tetramerization and transforming activity of RUNX1-ETO by expression of an ETO multimerization domain (Wichmann et al., 2007) . FRAP assays with CFP-PAX5-DDBD-C20S in the same cells as YFP-PAX5-C20S confirmed that the stability of YFP-PAX5-C20S association with chroma-tin was decreased considerably, although it is unclear why recovery of fluorescence plateaued at B80% (Figure 7b) . Similarly, the rapid nuclear mobility of PAX5-DDBD-C20S (t 1/2 B1 s) was decreased substantially by co-expression of an equal amount of CFP-PAX5-C20S (t 1/2 B25 s, Figure 7c ). The specificity of this effect was demonstrated in experiments with YFP-PAX5-p53tetra whose DN activity was not affected by PAX5-DDBD-C20S (Figure 7d ). These data confirm that multimerization of the PAX5 DBD causes stable chromatin binding, and demonstrate that disruption of the multimerization interface is sufficient to reverse PAX5-C20S DN activity.
Discussion
The requirement for induced oligomerization of oncogenic TF fusions for DN activity was originally identified in studies of RARa and RUNX1 fusions (Lin and Evans, 2000; Minucci et al., 2000) . Some of the oligomerization domains fused to the RARa DBD contribute to DN activity by enhancing recruitment of corepressors, such as SMRT, binding partner RXR, and by relaxing the DNA binding specificity compared with wt RARa/RXR (Lin and Evans, 2000; Minucci et al., 2000; Kamashev et al., 2004; Zhou et al., 2006; Martens et al., 2010) . Here, we present evidence that for DN PAX5 fusions, oligomerization of the DBD alone is sufficient to suppress activation by wt PAX5, and consequently, to contribute to leukemogenesis, without invoking recruitment of corepressors. We propose that PAX5 DBD oligomerization to a tetramer (PAX5-C20S, PAX5-p53tetra) or higher order multimer (PAX5-ETV6 SAM domain) results in an B10fold increase in affinity for PAX5-binding sites through interactions of the additional DBDs in the oligomer with neighboring non-specific sites in DNA, competing with wt PAX5 to target genes.
Gel filtration chromatography of recombinant PAX5-C20S purified from E. coli indicated that the fusion protein forms a stable tetramer. Further evidence that PAX5-C20S is a tetramer comes from the observation that YFP-PAX5-C20S co-eluted from the gel filtration column with an YFP fusion protein of the same N-terminal region of PAX5 to the well-characterized p53 tetramerization domain. This led to a great increase in the stability of chromatin binding by the fusion proteins compared with wt PAX5 as determined by FRAP assays in living cells. A similar finding was noted when the DBD of PAX5 was fused to the multimerization region of p53.
In vitro DNA-binding assays revealed that PAX5-C20S has B10-fold higher affinity for a PAX5-binding site in plasmid DNA compared with the monomeric PAX5 DBD. Consequently, the increased stability of chromatin binding by PAX5-C20S may be accounted for largely by the increase in DNA-binding affinity of the tetramer compared with the monomer. This increased DNA-binding affinity probably involves cooperative binding of more than one DBD in the PAX5-C20S tetramer to DNA, as no difference in affinity was observed for an oligonucleotide containing the same high-affinity PAX5-binding site, but which was too short to interact with more than one DBD. Further, the increase in affinity is probably due to interactions between DBDs in the multimer and neighboring nonspecific sites in a long DNA molecule as it was observed with a plasmid containing a single high-affinity consensus PAX5-binding site.
In hypothesis confirming studies, we noted no change in the stability of chromatin binding assayed by FRAP by mutation of potential corepressor binding sites in the PAX5-C20S sequence. But, a single leucine to proline mutation (L421P) in the predicted amphipathic a-helical tetramerization domain inhibited YFP-PAX5-C20S stable multimerization and greatly decreased the stability of binding to chromatin. Strikingly, when the PAX5 N-terminal region was fused to p53 domains or fibritin that generated a dimer, a trimer or a tetramer, the stability of chromatin binding and the DN activity of the fusion protein increased in parallel. Consequently, the increased stability of chromatin binding by PAX5-C20S compared with wt PAX5 seems best explained by the increased DNA-binding affinity of the tetramer compared with the monomer, without invoking binding by a corepressor. Our experiments with another PAX5 fusion (PAX5-ETV6) suggest that it too behaves as a DN in a similar manner. Earlier, we observed by chromatin immunoprecipitation that PAX5-C20S expressed at a similar concentration to endogenous wt PAX5 in cultured B cells, significantly reduced binding of wt PAX5 to its cognate binding site in the Blk gene (Kawamata et al., 2008) . The results discussed above strongly suggest that this decrease is due to competition for binding to the same site by PAX5-C20S, which binds to a PAX5 site in chromosomal DNA with B10-fold higher affinity than the monomeric PAX5 DBD in wt PAX5.
Earlier FRAP studies of other fusion proteins associated with hematopoietic malignancies have been reported including RARa fusions to PML, PLZF, NPM, NuMA or STAT5b in acute promyelocytic leukemia (Dong et al., 2004; Huang et al., 2008) , RUNX1 fusions to ETO and MTG16 in acute myeloid leukemia (Qiu et al., 2006) , and, recently, a PAX5-PML fusion (Qiu et al., 2010) . In most cases, only modest decreases in nuclear mobility compared with the wt TF were observed. Only in the cases of PML-RARa and PAX5-PML was the decrease in nuclear mobility as dramatic as observed here for PAX5-C20S and PAX5-ETV6. Moreover, as for PAX5-C20S, the unusually slow nuclear mobility of these fusions to PML is dependent on an amphipathic helical domain contributed by the PML fusion partner (Huang et al., 2008; Qiu et al., 2010 ) that oligomerizes into a tetramer (Antolini Figure 7 The C20S tetramerization domain suppresses the DN activity of PAX5-C20S. (a) Vectors for PAX5-wt, PAX5-C20S and PAX5-C20SDDBD and the luciferase reporter were transfected into 293T cells as indicated and luciferase assayed after 24 h. FRAP assays for (b) YFP-PAX5-DDBD-C20S (orange circles, N ¼ 3, t 1/2 B1 s), YFP-PAX5-C20S co-expressed with fourfold more CFP-PAX5-DDBD-C20S (YFP FRAP gray diamonds, N ¼ 7, t 1/2 B4 s) and YFP-PAX5-C20S (black circles, N ¼ 4, t 1/2 B200 s) and for (c) YFP-PAX5-DDBD-C20S (orange circles, N ¼ 3, t 1/2 B1 s), YFP-PAX5-DDBD-C20S and an equal amount of CFP-PAX5-C20S (gray circles, N ¼ 8, t 1/2 B25 s), and YFP-PAX5-C20S (black circles, N ¼ 4, t 1/2 B200 s). (d) PAX5-wtp53tetra was expressed with wt PAX5 and PAX5 reporter gene either with or without PAX5-C20SDDBD and luciferase assayed. A full colour version of this figure is available at the Oncogene journal online.
Dominant-negative mechanism of PAX5 fusions N Kawamata et al et al., 2003) . In other cases of ALL, PAX5 is fused to other partner genes that provide multimerization domains, including FOXP1 and the extracellular protein Elastin (Strefford et al., 2009) . Many of the other PAX5 fusion partners associated with ALL (ZNF521, JAK2, BRD1, DACH1, DACH2, GOLGA6 and KIF3B) contain putative, as yet uncharacterized oligomerization domains. Our findings are probably applicable to many other oncogenic fusions containing the DBD of a TF and a multimerization domain of the other partner. Since disruption of PAX5 DBD multimerization nearly eliminated the DN activity of PAX5-C20S, pharmacologic interference with multimerization of the PAX5 fusion proteins, or indeed any similar oncogenic fusion might be a novel therapeutic approach.
Materials and methods
Detailed procedures are in Supplementary Information.
Cell lines and transfection
293T and H1299 (p53 À/À ) cells were transfected with Effectene (Qiagen, Valencia, CA, USA) or Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturers' protocols. Burkitt B-cell line, Daudi, was maintained in RPMI-1640 media with 10% fetal calf serum. Six micrograms of YFP, YFP-PAX5-p53tetra or YFP-PAX5-C20S constructs was transfected into 3 Â 10 6 Daudi cells using Amaxa Nucleofector (Solution L and Condition A20) according to the manufacturer's recommendation (Lonza, Basel, Switzerland).
Vectors
Wt PAX5 cDNA was cloned into the pMSCV vector (Clontech, Mountain View, CA, USA). All YFP or CFP containing constructs were cloned into pcDNA3.1 (Invitrogen).
Luciferase reporter assays
Three PAX5 recognition sites derived from the murine CD19 promoter were placed in front of firefly luciferase in pGL2basic (Promega, Madison, WI, USA) (Dorfler and Busslinger, 1996) with pRenilla-luciferase-SV40 (Promega) used as a transfection efficiency control. Luciferase activities were measured using Promega Dual Luciferase reporter assay kit.
Fluorescence Recovery After Photobleaching
In these experiments, a region of fluorescent proteins within the nucleus is irreversibly bleached by a short, intense laser pulse, and recovery of fluorescence in the bleached region is monitored over time. After photobleaching, bleached molecules dissociate from their binding sites and are replaced by non-bleached fluorescent proteins that diffuse from outside the bleached region. Proteins that are highly mobile generate fast recovery curves while proteins tightly bound to anchored sites in the nucleus, such as chromosomes, recover slowly (Sprague and McNally, 2005) . Live 293T or H1299 cells were imaged 24 h post-transfection (800 ng vector per dish) with a Leica TCS SP2 AOBS single photon confocal microscope (Leica Microsystems GmbH, Wetzlar, Germany) with the stage and 63 Â 1.4-numerical aperture oil immersion objective placed in an enclosed chamber pre-equilibrated to 37 1C with continuous flow of 5% CO 2 over the microscope stage.
Fluorescence resonance energy transfer 293T cells were transfected using Effectene. Living cells were suspended in phosphate-buffered saline and assays performed on FACStar as described (Siegel et al., 2000) with 436 nm laser excitation and emission detected with 480 nm (x axis) and 535 nm (y axis) filters.
Electrophoretic mobility shift assays
Electrophoretic mobility shift assays were performed with a 46-bp probe containing one PAX5-binding site as described (Czerny et al., 1993) using recombinant proteins purified by Ni þ 2 affinity and gel filtration chromatography.
Cell sorting and semi-quantitative RT-PCR YFP-positive transfected Daudi cells were sorted by FACStar Cell Sorter (Becton, Dickinson and company, Franklin Lakes, NJ, USA). Total RNA was extracted and complementary DNA was generated using SuperScript III One-Step RT-PCR system (Invitrogen). Expression levels of b-actin in each samples were examined by 25 cycles of PCR; expression levels of two PAX5 downstream target genes, Blk and BCAR3 genes, were also examined by 30 and 32 cycles of PCR amplification, respectively. Ten microliters of each of the PCR products was run in 2% gel. PCR products were photographed and density of each PCR band was measured by NIH image software (http://rsb.info.nih.gov/nih-image/index.html).
